Sanara Medtech Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sanara Medtech Inc 's ROA in the second quarter of 2026?
Sanara Medtech Inc recorded a cumulative net loss of $-32 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -45.4%.

However, within the Healthcare sector 531 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3834, from total ROA ranking in the first quarter of 2026 at 4521.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-31.51 %	-28.73 %	4.16 %	-21.06 %	34.98 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-32	-34	-38	-38	-10
Return On Assets (TTM)	-45.4 %	-42.8 %	-43.97 %	-44.45 %	-11.32 %
SMTI's Total Ranking	# 3834	# 4521	# 3933	# 3336	# 3447
Total Assets (TTM) in million	69	69	73	71	101
Seq. Total Assets Change	-0.47 %	-5.03 %	2.83 %	-29.54 %	3.57 %
Seq. Net Income Change	-	-	-	-	-

SMTI's 5 Years Annual ROA >> Back to SMTI Management Effectiveness >> Compare SMTI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 139
Sector	# 532
Overall	# 3836

Return On Assets Statistics
High	Average	Low
18.41 %	-62.46 %	-322.52 %
(Jun 30 2017)		(Dec 31 2013)

Financial Statements
Sanara Medtech Inc 's Assets	$ 69 million	SMTI's Balance sheet
Sanara Medtech Inc 's Income	$ 0 million	Quarterly SMTI's Income Statement
SMTI's Income by Division		See SMTI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-3.55 %	19.99 %	16.84 %	43.27 %	371.57 %
Total Assets in million	85	89	74	63	44
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-38	-10	-4	-8	-8
Annual Return On Assets	-43.94 %	-11.18 %	-6.01 %	-12.8 %	-18.11 %

SMTI's 5 Years Annual ROA >> Back to SMTI Management Effectiveness >> Compare SMTI ROA to its Competitors

More Return On Assets Ratios
SMTI's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SMTI's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SMTI's Competitors
Subscribers only: Roa for Sanara Medtech Inc 's Suppliers
Subscribers only: Return On Assets for SMTI's Customers

You may also want to know
SMTI's Roi	SMTI's Inventory Turnover Ratio	SMTI's Growth Rates	SMTI's Dividend Comparisons
	SMTI's Profitability Ratios	SMTI's Asset Turnover Ratio	SMTI's Dividend Growth
SMTI's Roe	SMTI's Valuation Ratios	SMTI's Financial Strength Ratios	SMTI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T00:15:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.